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Background: For many common global diseases, such as cancer, diabetes, neurodegenerative and cardiovascular
diseases there is an unmet need for diagnosing early indications of disease that could enable medical intervention
and early treatment. The treatment of these diseases will require detailed knowledge of targeted pathways involved
in disease pathogenesis but also the mode of drug actions at the biological location on these targets. Translational
medicine is a new area of research where expert from different disciplines involved in basic science and clinical
disciplines meet and join forces. Mode-of-drug-action mechanisms elucidation is key in the characterization of drugs
that can relate to both efficacy and safety.
Methods: Matrix assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was used providing
evidence into the fate (destinations and distributions) of administered drugs within tumor regions of lung
compartments.
Results: We hereby present a pulmonary study in which we have isolated lung tissue after inhaled drug
administration and then localized the drug within airway wall compartments. The histology also provides evidence
of drug binding to smooth muscle cell microenvironments. We also identified lung tissue regions with tumor cell
invasion in these COPD patients.
Conclusions: The ultimate goal is to identify bridging comprehension that forms a knowledge base that can be
used by society to develop a better treatment and medicine for patients. Our results demonstrated that robust
imaging data could be generated confirming drug localization in pulmonary regions of COPD patients with tumor
pathology.
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Translational medicine (TM) is not really a new research
area, but rather a compilation of a number of research
areas that the scientific community has been involved in
for the last decades, in the clinic, academia as well as in-
dustry. TM is in general referred to as the medical prac-
tice that builds on a work-flow that involves evidence-
based medicine derived from linking knowledge about
disease pathways observed clinically with laboratory
models of disease that eventually develops into new
intervention and treatment paradigms [1].
Personalized medicine is in this context linked to a tar-
geted treatment: where a protein target is selected that
has key regulating roles within a specific disease [2-5].
TM is a research area that integrates basic research as
well as social and societal infrastructures where the goal is
to improve and deliver optimal patient care [6,7]. In this
respect, the concept of 4P Medicine has been introduced:
preventive measures which may extend beyond primary
healthcare services to preventive measures limiting disease
onset [8]. The translational area is highly timely, as the
modern healthcare area worldwide has many shortcomings
in terms of efficiency, both for the patient as well as for the
community that needs to bear the total cost for care.
By directing TM into the pulmonary diseases, we have
been actively driving these developments for the last dec-
ade, where the starting point for us has been the patho-
physiology and disease [9-17].
This is especially relevant to diseases such as lung can-
cer and chronic obstructive pulmonary disease (COPD),
the latter, a disease that is rapidly increasing, and that
present itself in combination with lung cancer. These
pulmonary diseases currently carry a huge mortality and
significant cost to the healthcare system. Cigarette smok-
ing is the most important risk factor in the development
of a number of major life threatening diseases including
cancer, COPD, coronary heart disease and stroke. As an
example, smoking prevalence in Estonia, EU in adults in
2005 was 31.5 % (42 % in male, 21 % in female) and in
youth 24 % (boys 30 % and girls 18 % from age [15-18].
These numbers have continued to increase since that
time. Quite often patients develop clinical complaints
related to smoking long after pathological damage has
begun. Disease related to smoking is heterogeneous within
individual patients with wide variety of co-morbidity in-
volving any and all of the above-mentioned disorders. The
time frame required for disease development also differs
between individuals by smoking history, age, gender, diet,
genetic background, and environmental exposure. The sta-
ging of disease is most often determined by clinical symp-
toms using a variety of measurement devices.
The big challenge dealing with translational science is
to be able to align and correlate the predictions of dis-
ease biology and possible treatment windows seen inanimal models with disease presentations and treatments
available in everyday clinical practice. The phenotyping
of individual disease presentations within the range of
spectrums of possible diseases will be a key component
of aligning effective therapy and in developing novel
drugs. It is in this arena that TM will have its future op-
portunities to bring ideas, innovations and best clinical
practice into an organized research structure. A structure
that utilizes the advanced platforms of science and tech-
nology that is coupled to a broad base of expertise that
crosses over between disciplines. The novelty will be to
perform the work along the lines of a new direction in
thinking, where the boundaries allow for a focused trans-
lation of our understanding of the mechanisms that
change healthy biology into diseased, and the ways of
impacting on these changes with targeted drug treatment
intervention [18].The current study provides new
insights to previously published work, with a drug
localization that is targeted towards smooth muscle cell
regions. In addition, this study also delivers imaging data
that provides evidence of tumor regions of lung com-
partments and MALDI-MSI selectivity and precision.Methods
Patients and clinical material
The bronchial tissue samples were biopsied from pa-
tients appointed to fiber optic bronchoscopy for different
clinical indications. In total, five patients were included
in this study, and phenotypes and diagnosis were as fol-
lows: two patients with suspicion to bronchial carcin-
oma, one for chronic obstructive bronchitis with
exacerbation, and two with sub-febrile body temperature
with unknown reason. Inform consent was obtained
from all patients (Tallinn Medical Research Ethical Com-
mittee decision #1724, from 18.06.2009). Before routine
bronchoscopy 1 mL of Berodual (Boehringer Ingelheim
Int. GmbH, Germany) solution, containing 250 μg/mL ipra-
tropium bromide (systematic (IUPAC) name, [8-methyl-8-
(1-methylethyl)-8-azoniabicyclo[3.2.1] oct-3-yl] 3-hydroxy-
2-phenyl-propanoate) together with fenoterol hydrochloride
500 μg/mL was administrated in the nebulized form via
PARI TurboBOYW inhalation device (total output rate
500 mg/min, with MMD 3.5 μm and 68 % mass percentage
below 5 μm, PARI GmbH) with nebulized medium of 0.9 %
NaCl (5 mL) and inspiratory flow 20 L/min for 10 minutes
(http://www.pari.de). After endobronchial inspection with
the white-light (WL) and autofluorescence image (AFI)
bronchoscope (Pentax) forceps (Olympos) bronchial biop-
sies were obtained from right upper lobe carina followed by
slow freezing over two minutes by floating in a bath of
super-cooled with dry ice isopentane. Bronchial tissue sam-
ples were then stored at −70 °C until sectioning.
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Cryostat thin slices of 10-μm thickness were prepared
using a Leica CM5030 cryostat. Serial sections were
placed upon frosted end microscope slides (Menzel-Gläser)
and air-dried. Then 500 μL of 7.5 mg/mL α-cyano-4-
hydroxycinnamic acid (CHCA) matrix solution in 50 %
acetonitrile/0.1 % trifluoroacetic acid was sprayed stepwise
onto the tissue sections by using an Aztek airbrush model
A4709 (Testor Corp., Rockford, IL), releasing short puffs
of matrix solution interrupted with 3–5 s dwell time.
Tissue sections prepared with matrix were allowed to dry
at room temperature in vacuum for an hour prior to
MALDI-MS analysis.
MALDI-MS drug characterization and imaging analysis
A MALDI LTQ Orbitrap XL mass spectrometer
(Thermo Scientific, Bremen, Germany), equipped with a
60 Hz 337 nm nitrogen pulse laser (LTB Lasertechnik
Berlin GmbH, Berlin, Germany), was used in this study
for compound tissue imaging. Imaging of drugs was per-
formed in both MS and MS/MS data collection in posi-
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Figure 1 Illustration presenting the experimental workflow of MALDI-arrays without laser movement in measuring position.
The FT mass analyzer (Orbitrap) was utilized at 60,000
resolution collecting spectral data in the mass range of
250–1000 Da generated by 20 laser shots at 10 μJ. The
linear ion trap analyzer was operated in the 90–500 Da
mass range and utilized to fragment the parent ion of
ipratropium (m/z 332.332) at normal scan rate, isolating
the ions in m/z 3.0 width. Normalized collision energy
was 50 % during an activation time of 30 ms and activa-
tion Q of 0.250 was applied with wideband activation.
The ImageQuest™ software (Thermo Scientific, San José,
CA) was used to create reference optical images of the
sample including the region of interest outlined for ana-
lysis of the drug parent and fragment ions.
The overall experimental strategy that was developed
within the study is illustrated in Figure 1.
Results and discussions
Linking disease phenotypes with diagnosis and transla-
tional predictions.
It is clear from a historical background that in the fu-
ture biomedical sciences will be driven by the ability to Sectioning 
Matrix deposition MALDI MS  
analysis 
MS imaging analyzing drug levels in patient lung tissues.
Figure 2 Schematic illustration of pulmonary disease
progressions.
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huge amounts of data outputs from clinical samples.
One major consequence will be to utilize the new tech-
nology deliveries as the basis to understand the disease
complexity and to develop new treatments. COPD is a
major concern in the world because of the high value of
smoking prevalence rate. Clinically these patients experi-
ence breathlessness, productive cough, shortage in many
life functions especially those associated with constitu-
tional capability. The diagnostic tools currently address
structural (CT lung density scan, CT airway wall thickness)
and functional abnormalities (spirometry for expiratory
flow, residual volume (RV), total lung capacity (TLC),
forced residual capacity (FRV), and airway specific resist-
ance and conductance). These diagnostic approaches are
valid in the more advanced COPD leaving, however, out
the early onset of lung functions decline in chronic smo-
kers who destined to but have not yet developed irrevers-
ible changes in lung structure and function. The
development of new protein biomarker assays that could
diagnose early ongoing disease greatly assist here and add
context to and complement the existing diagnostic tools.
The CT scans that are typically used in lung density mea-
surements in smokers will provide information on the dis-
tribution of emphysema, but will not differentiate between
older inactive emphysema lesions and active areas of
current parenchyma destruction. Protein measurements
capable of providing quantitative information on current
ongoing lung tissue matrix destruction would be invalu-
able assets in monitoring progression of disease in the
context of the CT scans measuring emphysema and the
functional tests.
Over recent time, it has been demonstrated that
early detection, prescription of personalized medicine
based on disease type, and evaluation of response to
treatment has significantly impacted on advancing
outcomes, and reducing cost to healthcare systems.
These diseases are known to be highly complex and
multifactorial. It is not possible at this stage, to as-
sign a single molecule related to one disease or clin-
ical complaint. On the contrary there are hundreds
(multiple signals), that relate to a change of a normal
state to a diseased. Consequently, there is a need of
selecting the key regulators from multiple signals.
This is a highly demanding task, as this is hampered
by the lack of tools and data for defining the bio-
logical mechanisms involved in the early onset of
establishing of disease development. This is probably
the biggest challenge within the field of translational
medicine.
In addition, the modeling of disease progression and
the evaluation of treatment response are also active areas
within the science community. Lung cancer and COPD
are both known to cluster in families and are morecommon in elderly population. Aggregation has been
observed in families which would suggest a genetic or an
environmental connection.
Clinically and pathologically it has been observed
that smokers with COPD often develop lung cancer.
The transition between normal epithelial cell biology
and transformation into a malignant cell status can
be defined histologically (Figure 2), as morphological
changes developing hyperplasia, followed by dysplasia
and a final diagnosis of carcinoma. Diagnostically,
these changes can be observed microscopically at
pathology examination but also macroscopically in
situ at the sites of disease by changes in fluorescent
patterns seen by endoscopy [19,20].
Currently these disease areas are facing significant
challenges where major research resources are directed,
such as:
1. Stratifying large and increasing number of lung
cancer phenotypes and their link to COPD
2. Diagnosis, at an early stage, where limited markers
are available, with a need for potential targeted
medical opportunities
3. Lack of monitoring of any given treatment’s
effectiveness
4. Correlation between in-situ molecular mechanism of
the disease and peripheral molecular changes
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changes have occurred at sites of targeted drug
intervention.
The optimization of treatment, based on individual
medical need is currently a fundamental cornerstone to
the rebuilding of the entire medical and clinical system.
In this respect, the concept of personalized medicine has
been established as a standard working proposition
worldwide. On the technology side, a major and unre-
mitting effort is underway to achieve these developments
such as the requirement to establish the standard ranges
of expression in quantitative assays. These assays need to
be able to separate healthy from diseased individuals in a
variety of basic sciences such as genomics, proteomics,
and metabolomics, as well as clinical sciences. Clinically,
surveillance, diagnosis and treatment are in focus, which
are in turn applied to match scenarios of individual dis-
ease with best practice treatment efficacy at the level of
each individual patient. Lately, a major focus of the
introduction of targeted personalized medicine is markerFigure 3 Illustration of translation medicine and its impact on novel dassociations with drug efficacy and safety. In this respect,
the interface that relates the localization of drugs and
metabolites that can be related to pharmacokinetic-, and
pharmaco-dynamic data will form the basis for optimal
conditions whereby drug dosing and delivery could be
made. In particular, targeted drug treatments, that is
directed towards a specific patient groups will benefit
from a predictive guidance utilizing matrix assisted laser
desorption/ionization mass spectrometry imaging (MALDI-
MSI). As mass spectrometry imaging does not require any
chemical labeling, the “cold compound” has the great ad-
vantage to provide data that can be directly linked to the
pharmacological effects of the drug.
Drug localization by MALDI-MS imaging
For many drug therapies, there is little knowledge about
the ultimate distribution patterns of the compounds
within tissue compartments following treatment. It is
possible to label drugs with a tracer and follow their up-





































#2819 LS: 25 ST: 1.43 uS: 1 NL: 1.58E6










































rug development and protein biomarker diagnostics.
Figure 4 Airway wall biopsies of two subjects treated with inhaled ipratropium detected by MALI-MSI. One sample (A-C) with intact
airway wall showed specific ipratropium mass fingerprint (m/z 332.22) while subject with airway tumor (D-F) showed no drug uptake.
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these methods the physical manipulation of the com-
pound by the labeling could change the properties of the
compound. Over the last decade a method to identify
unlabeled drugs in tissue has been under development
using MALDI-MSI. With MALDI-MSI continual incre-
mental sampling can be performed upon tissue takenFigure 5 Images showing the endobronchial images of chronic obstru
(B) bronchoscopy. Endobronchial images of bronchial carcinoma at the ri
bronchoscopy.directly from the body to identify cellular locations that
contain the specific drug ion signatures of the compound
in question [21].
We recently performed a proof-of-principle in order to
test the power of applying MALDI-MSI to demonstrate
the qualitative drug distribution within pulmonary
microenvironments. The concept and mass spectrometryctive endobronchitis with white light (A) and autofluorescence
ght upper lobe shown with white light (C) and autofluorescence (D)
Figure 6 Ipratropium identification within the pulmonary compartment with smooth muscle cells: (A) parent ion (m/z 332.332) and (B)
fragmentation pattern (m/z 124, 17, 152, 22 166.2 and 290.2).
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reported study in man, at a resolving power of 30 μm, of
drug localization within organ compartments using nor-
mal clinical dosing schemes and standardized laboratory
measurement. We mapped the occurrence of an inhaled
bronchodilator, the muscarinic receptor antagonist ipra-
tropium, within human bronchial biopsies obtained by
fiber optic bronchoscopy shortly after dosing exposure
[22]. Samples coated with a matrix compound were ana-
lyzed by a MALDI LTQ Orbitrap XL mass spectrometer
at a resolving power of 30 μm, spatial resolution. Ipratro-
pium parent ion (m/z 332.332) and daughter ions (m/z
166.2 and 290.2) were coincidently partitioned within the
sub mucosal spaces containing targeted airway smooth
muscle in 4/5 subjects. We could conclude from our
investigations that ipratropium is rapidly absorbed into
the airway wall. Of interest here was that the airway bi-
opsy not showing ipratropium uptake was histologically
found to represent a tumor forming within the airway
wall (see Figure 4). The limited drug uptake in the tumor
could be due to a variety of reasons including defects in
drug transport and changes in muscarinic receptor dens-
ity within the effected tissue microenvironment. The
ability to discriminate between positive and negative
examples of drug uptake provides a very powerful tool in
understanding drug efficacy.
We could also conclude from our study that the spe-
cific region of tissue isolation (from the patient presented
in Figure 4, where the tumor growth was identified), that
the tumor could be visualized in real-time upon
endobronchial biopsy isolation.
With endobronchitis imaging, using the white light
source in comparison to autofluorescence, tumor differ-
entiation can be made, by identifying the tumor regions
within microenvironments of the bronchi. Figure 5 pro-
vides a nice example and illustration of a healthy endo-
bronchial image using white light (Figure 5A) in relation
to the autofluorescence bronchoscopy (Figure 5B). The
COPD patient, with tumor growth, is illustrated in
Figure 5C in relation to Figure 5D, that provides evi-
dence of the tumor region. This can be seen as a white
region on the upper regions of image capture Figure 5C,
in comparison to the autofluorescence image (Figure 5D),
where this white region comes up as a black area. This is
the ultimate differential read-out that is used for tumor
diagnosis on a routine basis by clinicians.
The theoretical target of ipratropium was the muscarinic
receptors M1-M3 that are expressed differentially on
smooth muscle cells and inflammatory cells. Our results
showed that the ipratropium signal (typical mass spectra
of ipratropium in lung tissue presented in Figure 6) could
be observed in areas of the biopsy that coincidently con-
tained either or both, smooth muscle cells and/or inflam-
matory cells. Our current work is characterizing theexpression of the specific muscarinic receptor in this ma-
terial using immunohistochemistry. This is a powerful ad-
vantage of the MALDI-MSI technique in that the same
tissue section that has been used to quantify drugs can be
used in additional assays to characterize the
microenvironment.
Conclusions
Looking into the pipeline of drug products in develop-
ment and currently in clinical phase trials, the expecta-
tions of new treatments using Personalized Medicine
approaches of targeted medicines using either small
molecules as well as antibody-based biopharmaceuticals
are expected to grow considerably. It is envisioned that
the upcoming generation of personalized drugs for tar-
geted and stratified patient treatment will break through
in major disease areas such as, lifestyle-related cancers,
in particular lung cancers that has the highest mortality
including a the co-incident disorder chronic obstructive
pulmonary disease.
Mass spectrometric technologies can provide the
“phenotypic fingerprint” required for the concept of Per-
sonalized Medicine. Mass spectrometry-driven target
biomarker diagnoses in combination with high resolution
computed tomography could provide a critical pathway
initiative facilitated by a fully integrated e-Health infra-
structure system. By building experimental drug binding
property characteristics, prediction platforms can be
established that defines the “possible treatment
windows”.
The recent developments and announcement from the
Human Proteome Organization (HUPO), on the Human
Proteome Project (HPP) is a major undertaking [23].
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